Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amanda Trout

Interventional Pain Medicine San Juan, PR Doctor of Osteopathy

NPI 1699074823 CMS profile 1384117

954 Avenida Ponce De Leon, Ste 205- Pmb#10600, San Juan, PR 00906

Open in the dashboard

General payments

$6,152

385 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amanda Trout of San Juan, PR is reported in the CMS Open Payments database as having received $6,152 across 385 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 61st percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $21 1
2024 General $132 1
2023 General $165 11
2022 General $2,529 117
2021 General $2,007 155
2020 General $549 49
2019 General $749 51

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amanda Trout
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Amanda Trout were reported at $21. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Amanda Trout Interventional Pain Medicine median Middle half National median
2019 $749 $684 $216–$2,079 $163
2020 $549 $382 $122–$1,109 $114
2021 $2,007 $552 $167–$1,554 $132
2022 $2,529 $605 $187–$1,924 $149
2023 $165 $671 $195–$1,915 $160
2024 $132 $684 $206–$1,837 $164
2025 $21 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Abbott Laboratories $5,136 318 payments
  2. Boston Scientific Corporation $430 21 payments
  3. Medtronic USA, Inc. $198 11 payments
  4. Zyla Life Sciences $142 20 payments
  5. Medtronic, Inc. $95 5 payments
  6. Biodelivery Sciences International, Inc. $61 4 payments
  7. Pfizer Inc. $28 2 payments
  8. Novartis Pharmaceuticals Corporation $23 1 payment
  9. Kowa Pharmaceuticals America, Inc. $15 1 payment
  10. Biohaven Pharmaceuticals, Inc. $12 1 payment
  11. Other $12 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,635 381 payments
  2. Travel and Lodging $518 4 payments
Products named General payments · program years 2019–2025
  1. PROCLAIM Neuromodulation $2,347 115 payments
  2. Proclaim IPG $1,858 146 payments
  3. Proclaim Family of SCS IPGs $415 42 payments
  4. SPECTRA WAVEWRITER $279 14 payments
  5. OCTRODE $172 5 payments
  6. INTELLIS $145 8 payments
  7. SPRIX $136 19 payments
  8. PROCLAIM Neuromodulation $132 1 payment
  9. Octrode SCS Leads $73 3 payments
  10. General Therapies $65 1 payment
  11. Other $532 31 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

385 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Puerto Rico

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record